DealCellcolabs, a Stockholm, Sweden-based biotech company, secured $12 million in other-primary funding from Titian Capital, bringing its total funding to $37 million.
More on Tech.eu →
OTHER
10/31/2025
Flourish Care, a Boston-based women’s mental health platform, raised...
NanoZymeX, a Basel, Switzerland-based nanobiotech enzyme therapy platform,...
Cellbricks Therapeutics, a Berlin, Germany-based biofabricated tissue...
Ouro Medicines, a Cambridge, MA-based clinical-stage immunology biotech,...
Bioniq, a London-based personalised health platform, was acquired for $150...
Terns Pharmaceuticals, Inc., a Foster City, CA-based leukemia therapy...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
